Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy

Mizushima, Daisuke; Dung, Nguyễn Thị; Matsumoto, Shoko; Tanuma, Junko; Gatanaga, Hiroyuki; Trung, Nguyen Vu; Kính, Nguyễn Văn; Oka, Shinichi

doi:10.35772/ghm.2019.01035

Cited by 7 publications

(5 citation statements)

References 15 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of PIs has also been linked to increased CVD mortality and 30-day hospital readmission for heart failure [24]. The adverse CVD risk in PIs might partly be caused by disturbances in the lipid metabolism [25 ▪ ]. Atazanavir, unboosted or boosted by ritonavir, is an exception in the PI class as it was not associated with an increased risk of CVD in several studies [23,26].…”

Section: Cardiometabolic Side Effectsmentioning

confidence: 99%

Cardiovascular toxicity of contemporary antiretroviral therapy

Vos

Venter

2021

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of review HIV treatment has evolved since the introduction of antiretroviral therapy (ART) in the 1990s. Earlier treatment strategies, and the introduction of integrase inhibitors in preferred first-line ART have fundamentally changed cardiovascular side effects due to HIV infection and ART. This review provides an update on cardiovascular toxicity of contemporary ART. Recent findingsCardiovascular disease (CVD) risk, including heart failure, is still increased in people living with HIV (PLWH). Exposure to older antiretrovirals, including stavudine and zidovudine, still impact on CVD risk through persistent changes in body fat distribution years after discontinuation. Protease inhibitors (PI) and efavirenz have associated metabolic disturbances and increased risk of CVD, although use is decreasing worldwide. Integrase inhibitors and CCR5 antagonists seem to have negligible immediate CVD toxicity. Weight gain on newer antiretrovirals including integrase inhibitors is a reason for concern. SummaryCVD risk should be monitored carefully in PLWH who were exposed to first generation ART, efavirenz or to PIs. Registries should capture ART use and CVD events to stay informed on actual clinical risk in the current era of rapid initiation on integrase inhibitor-based ART.

show abstract

Section: Cardiometabolic Side Effectsmentioning

confidence: 99%

Cardiovascular toxicity of contemporary antiretroviral therapy

Vos

Venter

2021

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

show abstract

“…To apply the above formula with p=0.535: the prevalence of dyslipidemia according to a research ( 16 ), 53.5% of Vietnamese people had dyslipidemia (≥ 1 abnormal level of a serum lipid), α=0.05, d=0.10: absolute error, DE=2: design effect. Determination of the sample size in researching was based on the WHO guideline in the STEPwise approach to surveillance (STEPS).…”

Section: Methodsmentioning

confidence: 99%

Gender Differences in Risk Factors for Dyslipidemia in the Khmer Ethnic People, Vietnam

Nguyen¹,

Nguyen²,

Le³

et al. 2022

ijph

View full text Add to dashboard Cite

Background: The majority of the Khmer ethnic people living in the Mekong Delta had a difficult socio-economic life and limited access to information and health services. The study was conducted to determine the prevalence of dyslipidemia and risk factors in men and women of the Khmer ethnic people, in Vietnam. Methods: A cross-sectional study was conducted on 1.800 Khmer people aged 25 – 64 yr living in Tra Vinh Province in the Mekong Delta region of Vietnam. Data were analyzed using descriptive statistics and multivariate logistic regression. Results: The prevalence of dyslipidemia was high in men (47.3%) and in women (51.4%). Men had a higher prevalence of high TG (28.9% vs. 23.9%), whereas the prevalence of high TC (34.1% vs. 42.4%), and high LDL-C (28.2% vs. 37.9%) were lower in women, (all P<0.05). In men, dyslipidemia was significantly associated with central obesity (OR=2.58, 95% CI=1.32-5.06), overweight/ obesity (OR=2.50, 95% CI=1.75-3.56), and diabetes (OR=2.15, 95% CI=1.22-3.78). In women, dyslipidemia was significantly associated with diabetes (OR=2.14, 95% CI=1.08-4.24), central obesity (OR=1.69, 95% CI=1.18-2.42), overweight/ obesity (OR=1.50, 95% CI=1.06-2.10), and hypertension (OR=1.43, 95% CI=1.03-1.99). Age was significantly associated with increased risk of dyslipidemia in both genders. Conclusion: Overall, the prevalence of dyslipidemia among Khmer men and women adults aged 25 - 64 years in Vietnam was high. Our findings indicated an urgent need to have dyslipidemia prevention intervention programs for the Khmer ethnic people in the Mekong Delta, especially training about obesity and increasing healthy lifestyles.

show abstract

“…Nevirapine, a popular NNRTI, was noted to be lipid friendly as it increased HDL to a larger extent than LDL, and it did not promote insulin resistance [15]. Protease inhibitors (PI) are known to interfere with lipid metabolism, this partly contributes to their CVD risk factors [16]. PI use has been linked with increased CVD mortality and 30-day hospital readmission for heart failure [17].…”

Section: International Journal Of Scientific Advances Issn: 2708-7972mentioning

confidence: 99%

The Effect of HIV on the Heart and HAART on the Heart

Okun,

Kwabla,

Ogedegbe

et al. 2023

International Journal of Scientific Advances

View full text Add to dashboard Cite

HIV/AIDS is a disease characterized by immune dysfunction with superimposed severe opportunistic liability. The past few years has seen a significant rise to 75% of HIV patients compliant on ART. Delving into specific complications reveal significant associations between HIV and HAART in the heart. The purpose of this article is to throw more light on the key role players in cardiac dysfunction among HIV patients on HAART. In this article, we discuss the effects of HIV-associated chronic inflammation, immune dysfunction, high-risk medications, and their effects on the cardiovascular, and metabolic systems which further hastens the progression of cardiac dysfunction in individuals. Complications such as heart failure, coronary artery disease, pericardial effusion, and pulmonary hypertension are also discussed to appreciate the pathophysiology and outcomes. We believe that if more studies into cardiac complications of HIV patients on HAART are conducted, many patients will benefit from the evidenced-based outcomes which will influence clinical decision-making.

show abstract

Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy

Cited by 7 publications

References 15 publications

Cardiovascular toxicity of contemporary antiretroviral therapy

Cardiovascular toxicity of contemporary antiretroviral therapy

Gender Differences in Risk Factors for Dyslipidemia in the Khmer Ethnic People, Vietnam

The Effect of HIV on the Heart and HAART on the Heart

Contact Info

Product

Resources

About